Company news
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) news
Unicycive Therapeutics, Inc. news releases on 6ix. Latest, Oct 1, 2026: Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Press releases & updates
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
September 30, 2026
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
October 1, 2026
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
September 28, 2026
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
September 29, 2026
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
March 29, 2026
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
February 4, 2026
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
January 29, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
January 29, 2026
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
December 29, 2025
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
November 25, 2025
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
November 3, 2025
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
October 30, 2025
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
October 28, 2025
Unicycive Therapeutics to Participate in Upcoming Investor Events in September
August 26, 2025
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
August 18, 2025
Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
July 24, 2025
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 8, 2025
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
July 7, 2025
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
June 30, 2025
Unicycive Therapeutics, Inc. Announces Reverse Stock Split
June 17, 2025
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
June 10, 2025
Unicycive Therapeutics to Present at Upcoming Investor Conferences
May 22, 2025
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
May 21, 2025
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
April 10, 2025
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
March 31, 2025
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
March 13, 2025
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
February 20, 2025
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
January 27, 2025
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
January 6, 2025
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
December 16, 2024
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
November 20, 2024
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
November 10, 2024
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
October 27, 2024
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
October 15, 2024
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
October 13, 2024
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
October 8, 2024
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 23, 2024
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
September 15, 2024
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
September 2, 2024
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
August 25, 2024